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By global standards, the prevalence of community-onset expanded-spectrum-cephalosporin-resistant (ESC-R) Escherichia
coli remains low in Australia and New Zealand. Of concern, our countries are in a unique position, with high extramural resis-
tance pressure from close population and trade links to Asia-Pacific neighbors with high ESC-R E. coli rates. We aimed to char-
acterize the risks and dynamics of community-onset ESC-R E. coli infection in our low-prevalence region. A case-control meth-
odology was used. Patients with ESC-R E. coli or ESC-susceptible E. coli isolated from blood or urine were recruited at six
geographically dispersed tertiary care hospitals in Australia and New Zealand. Epidemiological data were prospectively col-
lected, and bacteria were retained for analysis. In total, 182 patients (91 cases and 91 controls) were recruited. Multivariate logis-
tic regression identified risk factors for ESC-R among E. coli strains, including birth on the Indian subcontinent (odds ratio
[OR] 11.13, 95% confidence interval [95% CI] 2.17 to 56.98, P 0.003), urinary tract infection in the past year (per-infec-
tion OR 1.430, 95% CI 1.13 to 1.82, P 0.003), travel to southeast Asia, China, the Indian subcontinent, Africa, and the
Middle East (OR 3.089, 95% CI 1.29 to 7.38, P 0.011), prior exposure to trimethoprim with or without sulfamethoxa-
zole and with or without an expanded-spectrum cephalosporin (OR 3.665, 95% CI 1.30 to 10.35, P 0.014), and
health care exposure in the previous 6 months (OR 3.16, 95% CI 1.54 to 6.46, P 0.02). Among our ESC-R E. coli
strains, the blaCTX-M ESBLs were dominant (83% of ESC-R E. coli strains), and the worldwide pandemic ST-131 clone was fre-
quent (45% of ESC-R E. coli strains). In our low-prevalence setting, ESC-R among community-onset E. coli strains may be asso-
ciated with both “export” from health care facilities into the community and direct “import” into the community from high-
prevalence regions.
Despite adramatic global rise in theprevalenceof expanded-spec-trum-beta-lactamase (ESBL)-producing Escherichia coli, infec-
tionsbyexpanded-spectrum-cephalosporin-resistant (ESC-R)E. coli
in Australia, NewZealand,North America, and selected European
countries remain at relatively low levels. Recent Australian na-
tional data show that 3.2% of community isolates carry such re-
sistance. Approximately 80% of these harbor a globally dominant
blaCTX-M ESBL gene and 12% a plasmid-borne AmpC-typemech-
anism (1). European surveillance data show that a significant pro-
portion of countries have ESC resistance rates rates below 10%
among invasive E. coli isolates (2). In the United States, a recent
large sample of E. coli isolates indicated that 3.9% were ESBL-
producing strains (3). Although these low rates offer reassurance
in the near term, a year-on-year rise in the incidence of commu-
nity-onset ESC-R E. coli infections in low-prevalence countries is
of concern (2, 4).
Australia and New Zealand are in a globally unique position. We
have low rates of useof antimicrobials traditionally identified as a risk
factor forESC-RE. coli. This includes very lowfluoroquinoloneuse
among humans and a ban on the use of ESC and fluoroquinolones
in food production (5, 6). In contrast, we have considerable extra-
mural pressure on antimicrobial resistance rates. Our countries
are located within the Asia-Pacific region, with which we share a
mobile population (7) and frequent commerce (although no land
borders). A high proportion of our regional neighbors have rates
of ESC-R among E. coli strains in excess of 25% (8, 9).
The aim of our study was to define the risk factors for, and
dynamics of, ESC-R among community-onset E. coli infections in
the low-prevalence settings of Australia andNewZealand by using
a case-control methodology. Furthermore, we characterized the
resistance genes and membership of the worldwide pandemic
clone ST131 in implicated isolates.
MATERIALS AND METHODS
The COOEE Study (COmmunity Onset ESBL and AmpC E. coli Study)
was a multisite case-control study, with prospective recruitment of pa-
tients and data collection. Six geographically dispersed tertiary centers in
Australia (n  5) and New Zealand (n  1) participated. The human
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research ethics committees at The University of Queensland and partici-
pating sites approved this study.
Definitions. E. coli infectionwas defined as “community onset” where
a patient was resident in the community (including nursing homes) or
had been hospitalized less than 48 h at the time of onset; “expanded-
spectrum cephalosporin resistance” included all “nonsusceptible” isolates
and was identified phenotypically. For ceftriaxone, MIC 1 mg/liter was
used. For ceftazidime, laboratories used MIC  1 mg/liter or MIC  4
mg/liter, depending on their use of EUCAST or Clinical and Laboratory
Standards Institute (CLSI) criteria, respectively (10, 11); “site of infec-
tion”was determined by the researcher from available information. Guid-
ance for urinary tract infections (UTI) was given as follows: “asymptom-
atic”  a positive urine culture, with no attributable symptoms; “lower
tract infection”  lower-urinary-tract-only symptoms such as urgency,
frequency, and dysuria; and “upper urinary tract infection”  tempera-
ture  38°C, flank pain, or costovertebral angle tenderness and/or any
bacteremia from a urinary source. “Immune suppression” referred to use
at the time of the sample collection of corticosteroids (15 mg/day pred-
nisolone or equivalent), calcineurin inhibitors, other nonbiologics (e.g.,
mycophenylate and methotrexate), cytotoxic agents, biological agents, or
radiation therapy; the Charlson comorbidity index (12) was calculated on
the basis of data available from the survey, with the exception of neuro-
logical impairment (dementia and hemiplegia), which was inadvertently
omitted from the survey questioning. AMcCabe score was assigned based
on the investigator’s estimate of participant survival (1month, 1month
to 2 years, or2 years) (13). “International travel” (excluding travel be-
tween Australia and New Zealand) was classified into geographical re-
gions as follows: South Pacific islands, southeast Asia, Indian subconti-
nent, China, Japan, North America, Europe, and Africa/the Middle East.
“High-risk travel” (regions of the Indian subcontinent, southeast Asia,
Africa, the Middle East, and China) was defined a priori based on Austra-
lian data (14). “Health care exposure” was assessed by the Friedman cri-
teria (15) with two modifications: (i) day procedures were recorded, and
(ii) the criteria were assessed in three “discrete” time periods (1 month
earlier, 1 to 6 months earlier, and 7 to 12 months earlier). In addition,
exact dates and details of any hospital admissions or surgical procedures
were recorded and the interval (in days) from the termination of health
care contact to the date of the firstmedical reviewwith the enrolling E. coli
infection subject was calculated. Further definitions are provided in the
supplemental material.
Clinical methods. A case-control methodology was used. Case pa-
tients with community-onset ESC-R E. coli in a culture of blood or urine
were identified in the microbiology laboratory of participating hospitals.
Control patients had community-onset ESC-susceptible (ESC-S) E. coli
isolated from the same specimen type (urine or blood) as the case. Con-
trols were not matched by any clinical presentation, comorbidity, or de-
mographic factors. They were selected as the next appropriate patient,
after an enrolled case patient, within the same laboratory’s specimen reg-
istration system. If the next appropriate control patient could not be re-
cruited, the process was repeated, at the same time of day and day of week,
in a later week of the study. A single control was recruited for each case.
Inclusions and exclusions. A laboratory-specific protocol was devel-
oped by each site to identify all potentially appropriate patients aged16
years with an isolate of ESC-R E. coli managed at the participating site.
Patients cared for by external health care providers such as family doctors
and external clinics (utilizing the participating laboratories as an external
provider) were not considered for recruitment, due to the complex hu-
man-research ethics requirements in our jurisdiction. Initial screening to
determine likely community onset and the presence of exclusion criteria
was by review of available electronic laboratory data and/or contact with
the clinician caring for the patient. Two exclusion criteria were applied: (i)
inability of the patient to give informed consent to participate, and (ii)
extra-anatomical urinary drainage such as an indwelling urinary catheter
(in the community), intermittent catheterization, ileal conduit, or similar.
These two groups whose members local clinicians had already identified
as a high risk factor for resistant infection appeared to have relatively
distinct demographic and health profiles. Hence, they were excluded in
order to focus study resources on a more generalized population group.
Data collection.Hospitalized patients or those attending ambulatory
clinics were approached for recruitment and data collection in person,
whereas the remainder were contacted by telephone. By telephone, at least
three contact attempts on different days were made. After informed con-
sent, including explanation of the aims of this study, a structured inter-
view was conducted using a standardized data collection form completed
by an investigator under non-blind conditions. Data were primarily self-
reported by participants. Where the participant was uncertain of details
(e.g., dates of hospitalization or antimicrobial use) or the details were not
clear to the investigators on the basis of the answer(s) provided, the inves-
tigators were able to review the patient’s medical records held at their
institution.
For intermittent exposures (e.g., travel, health care exposure, use of
antimicrobials, etc.), participants were asked to recall 12 months before
presentation. Exact dates of exposure were recorded. If the exact date was
not recalled, it was estimated (“start of month”  the 1st of the month,
“middle” or no date specified 15th, “end of month” last day).
Datawere forwarded to a central coordinatorwhere theywere checked
and entered into a secure database. Any omissions or discrepancies were
clarified with the individual sites.
Laboratory methods. All phenotypic susceptibility data presented in
this study have been assessed by EUCAST criteria (10). All nonsusceptible
isolates were considered “resistant” for the purpose of this analysis. E. coli
isolates from each patient were forwarded to the research laboratory, with
phenotypic identification and antimicrobial susceptibility undertaken by
the use of disk diffusion susceptibility testing (DST), an automated system
(VITEK 2), or agar dilution, based on the criteria in use by the laboratory
at the time. Where data for susceptibility to an ancillary antimicrobial
(e.g., nitrofurantoin) were not available, this was assessed by DST in the
research laboratory. Where an isolate was originally tested by CLSI, DST
using EUCAST criteria was undertaken (in the research laboratory) for
agents for which the nonsusceptibility breakpoints of these two criteria
differ (ceftazidime, cefepime, amikacin, gentamicin, ciprofloxacin, and
nitrofurantoin). Where stated, MICs were performed by Etest (bioMéri-
eux, France). For each isolate, a summative antimicrobial resistance score
was calculated from 11 antimicrobials tested (ampicillin, amoxicillin
plus clavulanate, ceftriaxone, ceftazidime, cefepime, meropenem, trim-
ethoprim-sulfamethoxazole [SXT], ciprofloxacin, nitrofurantoin, genta-
micin, and amikacin).
After overnight culture, bacterial DNA was extracted using an Ultra-
Cleanmicrobial DNA isolation kit (Mo Bio Laboratories). ESC resistance
genes were investigated by PCR using previously published primers and
conditions (16–18). A stepwise approach based on local epidemiology of
resistance mechanisms was employed. All isolates were investigated for
blaCTX-M-1 group and blaCTX-M-9 group genes. Isolates negative for these
were investigated for blaCTX-M (consensus sequence), blaCMY, blaDHA,
blaTEM, blaSHV, and blaVEB. All isolates were screened for carbapenemase
genes (blaNDM, blaKPC, and blaIMP) using an in-housemultiplex PCR (19)
and a singleplex PCR for blaOXA-48-like enzymes (20). All PCR amplicons
were sequenced in the forward and reverse directions using anABI3730XL
(Life Technologies) capillary sequencer and compared to published se-
quences in GenBank (www.ncbi.nlm.nih.gov/GenBank).
Presumptive ST131 E. coli isolates were determined by use of semiau-
tomated repetitive sequence-based PCR (rep-PCR) (DiversiLab, bioMéri-
eux, France). Isolates clustering within 95% similarity to multilocus se-
quence type (MLST)-confirmed ST131 reference clones, using a Pearson
correlation coefficient, were considered members of this clone (21). A
selection of isolates (n  4) were confirmed as ST131 by formal MLST
analysis (22).
Statistical methods. Sample sizes with overseas travel as a risk factor
for resistant infection were calculated. With an estimated annual rate of
overseas travel of 250/1,000 population (7), a sample size of 95 cases with
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matched controls was required to detect this risk with odds ratio  2.5
(power of 0.8 and two-sided alpha of 0.05).
Continuous data on health care exposure was right-censored at 365
days. Univariate comparison was undertaken by a 2 test, Fischer’s exact
test, Wilcoxon rank sum test, and logistic regression as indicated. Inter-
actionswere examined. Amultivariate logistic regressionmodel with vari-
ables significant in univariate analysis at a P 0.2 level was constructed.
Using backward selection, variables were retained in the final logistic re-
gressionmodel if their significance remained below P 0.2. Models were
assessed by calculation of a receiver operating characteristic (ROC) curve
and Hosmer-Lemeshow goodness of fit. All statistical tests were two-
tailed, and P  0.05 was considered significant. STATA version 12.1
(Statacorp) was used.
RESULTS
In total, 182 patients (91 cases and 91 controls) were recruited
between March 2011 and October 2012 (Fig. 1). Patients were
recruited over 12 continuous months at five sites and over 9
months at one site. Sites contributed between 8 and 58 patients.
Bacteremia was detected in 33 patients (18%), and positive
cultures were grown from urine samples collected from the re-
maining 149 (82%). Uneven numbers of bacteremias occurred as
one control patient recruited with a positive urine culture subse-
quently manifested a positive blood culture. The residences of the
patients before presentation, clinical syndromes of presentation,
and characteristics of hospital presentation did not differ signifi-
cantly between case and control patients (Fig. 1).
A further 43 patients with presumed community-onset ESC-R
E. coli infection and no overt exclusion criteria were not recruited
(declined to participate, n  19; not contactable, n  18; other,
n 6). On comparison with recruited study participants, the me-
dian age (56 years, P  0.81) and gender (11/43, 26% male, P 
0.39) did not differ significantly from those of the recruited pa-
tients and they were not analyzed further.
Close temporal matching of cases and controls was not fre-
quent. Samples from9 controls originated from the same calendar
day as those from the matched case. For the entire cohort, there
was amedian interval of 22 days between the dates of collection of
the case and control samples.
Phenotype, resistance genes, and ST131. All case patients’ E.
coli isolates demonstrated phenotypic ESC resistance (ceftriaxone
plus ceftazidime 60 [68%], ceftriaxone only 28 [32%], cefta-
zidime only  3 [3%]). For the three E. coli isolates with ceftazi-
dime resistance, the MICs of ceftazidime in the study laboratory
were256mg/liter, 2 mg/liter, and 0.25mg/liter, respectively. All
control patient isolates were susceptible to ceftriaxone and cefta-
zidime. For all antimicrobials studied, with the exception ofmero-
penem (100% susceptible) and amikacin (case  4 resistant/91
[4%], control  0 resistant/91 [0%], P  0.121), resistance was
significantly more likely in the ESC-R isolates than in the ESC-
susceptible (ESC-S) isolates. For ESC-R E. coli, there was signifi-
cant resistance to the oral therapeutic options investigated, in-
cluding amoxicillin plus clavulanate (ESC-R  59/91 [65%]
versus ESC-S 15/91 [16%], P0.001), ciprofloxacin (57/91
[63%] versus 6/91 [7%], P 0.001) and SXT (64/91 [70%] versus
20/91 [22%], P 0.01).
E. coli isolates from 89 cases (98%) and 90 (99%) controls were
available for further analysis. Carbapenemases were not detected
in any isolates. Expanded-spectrum cephalosporinase genes were
detected in 87 of 89 (98%) ESC-R E. coli isolates as follows: for
134 patients with ESC resistant E. coli in 
blood or urine identified for potential 
recruitment. 
91 CASES Recruited 
•  16 - bacteremia (18%) 
•  75 - urine only (82%) 
43 patients NOT recruited. 
•  19 declined to participate (44%)  
•  18 not contactable (42%)  
•  6  other reasons (14%)  
91 CONTROLS recruited 
•  17 - bacteremia (19%) 
•  74 - urine only (81%) 
Residence at time of presentation (n=182) 
•  170 – Private dwelling (93%) 
•  5 – Shared accommodation e.g. boarding house (3% )  
•  5 – Assisted living  (3%)  
•  2- Long term care facility (1%)  
Comparison of cases and controls p=0.549  
First healthcare provider for this presentation (n=182) 
•  100 - emergency department – enrolling hospital (55%) 
•  30 - outpatient clinic – enrolling hospital (16% )  
•  34 - family doctor (19%)  
•  18 - other locations (10%)  
Comparison of cases and controls p=0.553  
Case- Clinical syndrome* 
•  40 Lower urinary tract 
•  26 Upper urinary tract 
•  18 Asymptomatic urine 
•  3 Prostatitis 
•  4 Other 
Control- Clinical syndrome* 
•  34 Lower urinary tract 
•  24 Upper urinary tract 
•  23 Asymptomatic urine 
•  2 Prostatitis 
•  8 Other *p=0.81 for comparison of syndrome 
FIG 1 Participant identification and recruitment and characteristics of presentation and clinical syndrome.
Rogers et al.
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ESBLs, the blaCTX-M-1 group (36/89, 40%), blaCTX-M-9 group (35/
89, 39%), blaCTX-M-1 and blaCTX-M-9 group (3/89, 3%), and
blaSHV-5 group (n  1; 1%); and for non-ESBLs, the blaCMY-2
group (n  11; 12%) and blaDHA-1 group (n  1; 1%). The two
remaining samples included two of the three E. coli isolates with
ceftazidime resistance (MICs, 2 mg/liter and 0.25 mg/liter) and
contained only blaTEM-1, a non-expanded-spectrum beta-lacta-
mase. ESC nonsusceptibility most likely originated from hyper-
production of this enzyme, with loss of this trait during passage
and storage in the case of the isolate with the lower drug MIC.
The worldwide pandemic ST131 clone was presumptively
identified in 46 patients (24%), who were significantlymore likely
to be case patients than controls (40/89 [45%] versus 6/90 [7%],
P 0.001). Among ESC-R E. coli isolates, ST131 was not associ-
ated with any non-CTX-M enzymes. They constituted 54% of the
entire group of CTX-M isolates. In total, 24 (60%) harbored a
CTX-M-1 group enzyme and 19 (48%) aCTX-M-9 group enzyme
(P 0.173 for the comparison). This includes three isolates (8%)
harboring both enzymes. There was no significant difference in
the proportions of ST131 by sample type (blood versus urine, P
0.514) or hospital site (P  0.574). With the exception of the
smallest site (where 0 of 8 were ST131), the clone constituted 19%
to 32% of the isolates from each site.
Demographics, comorbidities, and antimicrobial use. Age
data were compared by visual inspection of histograms. Cases and
controls had similar bimodal distributions, with peaks at approx-
imately 25 and 65 years. Median and 25th to 75th percentiles for
ages of cases and controls, respectively, were 61 years (21 to 82)
and 59 years (19 to 87) (P 0.769). Results of univariate compar-
isons of demographic factors and medical comorbidities between
cases and controls are shown in Table 1. Male sex was the only
variable with a significant difference (odds ratio [OR] 2.3, 95%
confidence interval [CI] 1.5 to 4.6, P 0.018).
Risk from previous urinary tract infection, renal allograft
transplant, and anatomical abnormality of the renal tract was in-
vestigated (Table 1). The number of urinary tract infections in the
previous year was significantly associated with ESC-R E. coli, with
an odds ratio of 1.32 (95% CI  1.08 to 1.63, P  0.008) per
infection.
Results of univariate analysis of antimicrobial use in the previ-
ous year are shown in Table 1. Where the patient could not recall
the antimicrobial taken, it was recorded as “unknown.” Exposure
to trimethoprim or trimethoprim with sulfamethoxazole (SXT)
(OR 3.02, 95% CI 1.13 to 8.12, P 0.028) was a significant
risk factor for ESC-R E. coli. In addition, 7 of 7 patients who had
been exposed to an expanded-spectrum cephalosporin (ceftriax-
one, ceftazidime, or cefepime) had ESC-R E. coli isolated.
Health care exposure. Health care exposure was analyzed us-
ing two distinct sets of data. First, health care exposure, classified
using Friedman criteria for health care-associated (HA) infection,
was analyzed in three time windows, with and without the inclu-
sion of day procedures. Exclusion of day procedures performed
marginally better at predicting ESC-R; exposure 0 to 1 month
earlier (OR 3.56, 95% CI 1.14 to 11.14, P 0.029) and 2 to 6
months earlier (OR 2.99, 95%CI 1.50 to 5.98, P 0.002) was
associated with ESC-R E. coli whereas exposure 7 to 12 months
earlier (P  0.705) was not (full details are provided in the sup-
plemental material).
Second, a continuous model of the temporal risk of ESC-R E.
coli infection after health care exposure was generated using the
exact time interval since last hospital admission. Day procedures
were excluded based on the results of the first analysis. This
smoothed curve of the odds ratios shows the lower bound of the
95% CI approaching an odds ratio of 1.0 at approximately 4 to 5
months (Fig. 2).
Travel, community, andoccupational exposure.Travel in the
previous year was analyzed by region. Travel to the Indian sub-
continent approached but did not achieve significance (P 0.09).
Birth on the Indian subcontinent was a significant risk factor
(OR 6.119, 95% CI 1.32 to 28.44, P 0.021) (Table 1).
Occupational exposure to animals, medical patients, and po-
tential household risks was assessed, as was consumption of a va-
riety of meats. No factors were significant (Table 1). Probable
household transmission of ESC-R E. coliwas suggested in one case
where the partner of an enrolled patient had an infection with a
highly similar isolate (99% identical by rep-PCR usingDiversilab)
3 months prior.
Multivariate analysis. For the multivariate model, health care
exposure in the previous 6months, excluding day procedures, was
selected as a pragmatic option (univariate OR 2.95, 95% CI
1.59 to 5.46, P 0.001). This dichotomous measure was nonsig-
nificantly different from the four-categorymeasurement used ear-
lier (likelihood ratio test P  0.821). Travel to high-risk regions
was selected from the travel group (OR 1.97, 95% CI 0.94 to
4.11,P 0.071).Use of an expanded-spectrumcephalosporinwas
combinedwith use of trimethoprim and SXT, in order to enter the
former into the model, given its accepted prominence as a risk
factor for ESC-R E. coli infection.
Significant variables in multivariate analysis were health care
exposure, excluding day procedures in the previous 6 months
(P 0.002), birth on the Indian subcontinent (P 0.004), travel
to high-risk regions (P  0.011), SXT/ESC use (P  0.014), and
number of UTIs in the previous year (P  0.003) (Table 2). As-
sessment of the final model demonstrated an area under the ROC
curve of 0.77 and a nonsignificant Hosmer-Lemeshow goodness
of fit (P 0.289).
Interactions and alternativemodels.A significant correlation
between travel to high-risk regions and region of birth occurred.
Those born in high-risk regions were more likely to undertake
high-risk travel than those born elsewhere (17/28 [61%] versus
21/154 [14%], P  0.001). This was particularly noted for birth
and travel to the Indian subcontinent (7/13 [54%] versus 31/169
[18%], P  0.002). This correlation, and the use of differing pa-
rameters for health care contact and antimicrobial exposure, were
explored in alternative multivariate models (see the supplemental
material). Specific population subgroups (symptomatic patients
only, ESC-R blaCTX-M patients only, and ESC-R ST131 patients
only)were also tested in themodel.None of the alternativemodels
performed better than the final model, although the levels of sig-
nificance of health care exposure, male sex, and region of birth/
travel differed depending on the model parameters selected.
HAandnon-HAESC-RE. coli.Adifference in the levels of risk
of health care-associated (HA) ESC-R E. coli and non-HA ESC-R
E. coli was separately investigated by analysis of risks within the
HA (n  73) and non-HA (n  109) cohorts (full details are
provided in the supplemental material). Several of the identified
risks for ESC-R E. coli appeared to be most concentrated in one
cohort. Data corresponding to travel to high-risk regions (P 
0.001), birth on the Indian subcontinent (P  0.006), and male
sex (P 0.018) were statistically significant only among themem-
ESC-Resistant E. coli in Low-Prevalence Countries
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TABLE 1 Univariate analysis of demographics, comorbidities, antimicrobial use, region of travel and birth, occupational and household exposure
Subject variable
Frequency in ESC-R cases
(%) (n 91)
Frequency in ESC-S controls
(%) (n 91)
Odds
ratio 95% CI P value
Demographics comorbidities
Male sex 30 (33) 16 (18) 2.31 1.51–4.62 0.018b
Age 30 or 59 yrs 66 (73) 60 (66) 1.36 0.72–2.57 0.336
Immune suppression 19 (20) 10 (11) 1.99 0.87–4.60 0.105b
Charlson score 1 44 (48) 34 (37) 1.57 0.87–2.83 0.135b
Active malignancy 11 (13) 9 (8) 1.43 0.55–3.73 0.469
Renal failure 11 (13) 9 (10) 1.25 0.49–3.19 0.636
McCabe score 2 78 (86) 76 (84) 1.18 0.53–2.65 0.681
Indigenous 7 (8) 6 (7) 1.18 0.38–3.66 0.774
Heart disease 7 (8) 7 (8) 1
Long-term-care-facility resident 1 (1) 1 (1) 1
Smoker 12 (13) 14 (15) 0.83 0.36–1.92 0.672
Liver disease 3 (3) 4 (4) 0.74 0.16–3.41 0.701
Lung disease 5 (5) 7 (8) 0.70 0.21–2.85 0.552
Pregnant or postpartum 3 (3) 7 (8) 0.41 0.10–1.63 0.206
Renal tract background
Renal transplant 8 (9) 4 (4) 2.1 0.61–7.22 0.241
Anatomical or structural abnormality 23 (25) 15 (16) 1.71 0.83–3.55 0.147b
UTIs in past 12 mos (per UTI)c Median 1; IQR 0–3 Median 0; IQR 0–1 1.32 1.08–1.63 0.008b
UTIs in lifetime (per UTI)c Median 2; IQR 0–5 Median 2; IQR 0–5 1.03 0.90–1.18 0.657
Antimicrobial use
Any antimicrobials in past 12 mos 69 (76) 62 (68) 1.47 0.76–2.81 0.249
Trimethoprim sulfamethoxazole 16 (17.58) 6 (6.59) 3.022 1.13–8.12 0.028b
Expanded-spectrum cephalosporin(s) 7 (8) 0 NA 0.014b
Fluoroquinolone(s) 7(8) 3 (3) 2.44 0.61–9.77 0.206
-Lactam ß-lactamase inhibitor 16 (17.58) 11 (12.09) 1.552 0.68–3.56 0.300
Carbapenem(s) 3 (3.3) 2 (2.2) 1.517 0.25–9.30 0.652
Aminoglycoside(s) 5 (5) 4 (4) 1.26 0.33–4.87 0.733
Macrolide 6 (6.59) 5 (5.49) 1.214 0.36–4.13 0.756
“Unknown” antimicrobial(s) 35 (38) 33 (36) 1.1 0.60–2.00 0.759
Narrow-spectrum cephalosporin(s) 16 (17.58) 15 (16.48) 1.081 0.50–2.34 0.844
Narrow-spectrum penicillin(s) 10 (10.99) 14 (15.38) 0.679 0.28–1.62 0.383
Travel by regiona
Any overseas travel 28 (30.8) 22 (24.18) 1.39 0.72–2.68 0.32
High-risk regions 24 (26) 14 (15) 1.97 0.94–4.11 0.071b
Indian subcontinent 6 (6.59) 1 (1.1) 6.928 0.75–53.87 0.09
North America 5 (5.49) 2 (2.20) 2.199 0.49–13.69 0.264
Africa the Middle East 3 (3.3) 2 (2.2) 1.517 0.25–9.30 0.652
Southeast Asia 15 (16) 13 (14) 1.18 0.53–2.65 0.681
South Pacific 3 (3.30) 3 (3.30) 1
Europe 3 (3.30) 5 (5.49) 0.586 0.14–2.53 0.474
China 4 (4.4) 0 0.121
Japan 1 (1.1) 0 0.500
Birth by region
High-risk region 18 (20) 10 (11) 2.0 0.87–4.60 0.105
Indian subcontinent 11 (13) 2 (2) 6.12 1.32–28.45 0.021b
Australia New Zealand 58 (64) 59 (65) 0.95 0.52–1.75 0.877
Europe 15 (16) 18 (20) 0.80 0.38–1.71 0.564
Southeast Asia 3 (3) 4 (4) 0.74 0.16–3.41 0.701
AfricaMiddle East 2 (2) 4 (4) 0.49 0.09–2.74 0.415
China 2 (2) 0 0.497
South Pacific 0 3 (3) 0.246
Latin America 0 1 (1) 1.0
Occupation and household exposure
Partner with recent ESC-R E. coli infection 2 (2) Not assessed
Occupational health care exposure 10 (11) 7 (8) 1.48 0.54–4.08 0.447
(Continued on following page)
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bers of the non-HA group. Conversely, data corresponding to a
risk from SXT or ESC use were statistically significant only among
members of the HA group (P 0.026). The numbers of UTIs in
the previous yearwere nonsignificantly different among themem-
bers of either group assessed separately.
Correlates of the classes of ESC resistance enzymes. Corre-
lates of ESC resistance enzyme classes were investigated by a com-
parison of patients harboringE. coliwithCTX-Mgroup enzyme to
those harboring other enzymes (“non-CTX-M”  CMY, DHA,
SHV, TEM). Full details are provided in the supplemental mate-
rial.
There was no statistically significant difference with respect to
the site of infection between CTX-M-harboring and non-CTX-
M-harboring participants (P  0.473), and although bacteremia
was more frequent in the CTX-M group, this did not reach statis-
tical significance (15/73 [21%] versus 0/15 [0%], P  0.063). A
significantly higher median resistance score was present in
CTX-M isolates than in non-CTX-M isolates (median 6 [inter-
quartile range 5 to 7] versus median 4 [interquartile range
4 to 5], P  0.001). Notable differences included higher rates of
resistance to the non-beta-lactam oral agents ciprofloxacin (56/74
[76%] versus 1/15 [7%], P 0.001) and SXT (60/74 [81%] versus
4/15 [27%], P 0.001) among the members of CTX-M group.
In regard to potential risk factors, the members of the CTX-M
group were significantly more likely to have had health care expo-
sure in the previous 6 months than the members of the non-
CTX-M group (45/74 [61%] versus 3/15 [20%], P  0.005) al-
though the same was not true with respect to health care exposure
in the previous 12 months (P  0.72). Other factors used in the
multivariate model that trended toward significance among the
members of the CTX-M group included more high-risk travel
(P  0.052) and fewer reported UTIs in the previous 12 months
(P 0.054). Comparisons of factors not included in themultivar-
iate model showed that “any overseas travel” was more likely in
the CTX-M group (27/74 [36%] versus 1/15 [7%], P 0.033).
DISCUSSION
This multicenter prospective case-control study of community-
onset ESC-R E. coli infection has several key findings that have
implications for risk-based empirical antibiotic prescription and
infection control practices and for control of ESC-R E. coli infec-
tions within communities.
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FIG 2 The risk of ESC-R E. coli infection over a 12-month period after the
most-recent episode of health care exposure, excluding day procedures, esti-
mated with two data sets. The smoothed curve was calculated using continu-
ous data corresponding to the months since hospital admission (black line;
95% CI in gray). Discrete intervals determined using Friedman criteria are
indicated (black dots; 95%CI as vertical dashes). The dashed line represents no
increased risk (odds ratio 1.0).
TABLE 2 Multivariate logistic regression
Subject variable
Odds
ratio 95% CI
P
value
Health care exposure in the previous 6 mos 3.16 1.54–6.46 0.002
UTIs in previous yr (per UTI) 1.43 1.16–1.82 0.003
Birth on the Indian subcontinent 11.13 2.17–56.96 0.004
Travel to high-risk region(s) 3.09 1.29–7.38 0.011
Trimethoprim sulfamethoxazole ESC use 3.67 1.30–10.35 0.014
Male sex 2.17 0.97–4.84 0.060
TABLE 1 (Continued)
Subject variable
Frequency in ESC-R cases (%)
(n 91)
Frequency in ESC-S controls
(%) (n 91)
Odds
ratio 95% CI P value
Pet cat or dog or both at home 32 (35) 33 (36) 0.95 0.52–1.75 0.877
Occupational animal exposure 4 (4) 5 (5) 0.79 0.21–3.05 0.733
Preschoolers at home (5 yrs of age) 7 (8) 9 (10) 0.76 0.27–2.13 0.601
Food consumption
Any meat in past 12 mos 89 (98) 87 (98) 2.05 0.37–11.46 0.415
Poultry 88 (97) 83 (92) 2.47 0.62–9.89 0.206
Processed/preserved meats 51 (56) 52 (58) 0.93 0.52–1.68 0.814
Pork 60 (66) 63 (70) 0.83 0.44–1.55 0.558
Red meat 76 (84) 78 (88) 0.72 0.31–1.66 0.433
a Destinations of travel by region were as follows: for the Indian subcontinent, India, Pakistan, Nepal, and Bangladesh; for North America, the United States and Canada; for Africa
and the Middle East, Zimbabwe, Kenya, Sudan, Liberia, Turkey, and Afghanistan; for Southeast Asia, Malaysia, Singapore, Thailand, Laos, Cambodia, Vietnam, Burma, Indonesia,
and The Philippines; for South Pacific, New Caledonia, Papua New Guinea (PNG), Fiji, Samoa, Cook Islands, and boat cruises through the South Pacific; for Europe, the United
Kingdom, Italy, Holland, Portugal, and Poland; for China, China, Hong Kong, and Macau; for Japan, Japan. High-risk regions include the Indian subcontinent, Africa, the Middle
East, Southeast Asia, and China regions.
b Entered into multivariate model.
c Infections were recorded numerically on a scale of 0 to 5, with all 5 results considered 5 for analysis. Summaries are presented as a median value and an interquartile range
(IQR).
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First, we established that 6 months is a practical, evidence-
based definition for the duration of increased risk of a communi-
ty-onset E. coli isolate harboring ESC-R after health care exposure.
The time-dependent relationship of health care exposure to resis-
tance seems intuitive in nature; however, previously there has
been little supporting data. Hence, authors have used a variety of
definitions from 1 to 6 months (23–25).
Overall, the significant contribution of health care exposure
(OR  3.15) as an ongoing “exporter” of resistant infection in a
low-prevalence setting highlights the importance of controlling
ESC resistance in the health care system. Supporting this hypoth-
esis, United Kingdom data have recently demonstrated a broad-
based decrease in the rate of ESC resistance among invasive Enter-
obacteriaceae strains following a reduction in the use of ESC and
fluoroquinolones within the hospital system (26).
The “importation” of ESC-R E. coli after travel to countries
with a high community incidence of ESBLs is starting to be de-
fined (27), although fewer studies have identified infection rather
than carriage (25, 28, 29). While the pathophysiology seems clear,
the temporality of this remains to be confirmed. In our study,
analysis of temporality, as presented for health care exposure, was
precluded by the imprecision of data from the composite “high-
risk” group and the low numbers involved. However, in absolute
terms, 21 of 24 (87.5%) case participants with travel to high-risk
regions departed those regions within the 6 months before pre-
sentation of infection. This fits with our previous research dem-
onstrating mostly short-lived carriage of ESBL E. coli following
travel overseas and with other studies demonstrating a decrease in
the risk of resistant infection beyond 6 weeks after return from
travel (29, 30).
Investigation of risks for community acquisition in the low-
prevalence countries of Australia and New Zealand showed that
one-quarter (n  23) of ESC-R E. coli patients reported neither
health care exposure nor high-risk travel, suggesting there are as-
yet-undefined risk factors for transmission within the community
(25, 31).
While there was some correlation between birth and travel
region data, the identification of birth on the Indian subcontinent
(OR  11.12) as a risk factor for ESC-R E. coli infection in our
cohort appears genuine. The etiology of this risk could stem from
prolonged carriage of ESC-R E. coli after travel more than 1 year
previous, leading to delayed community-onset ESC-R E. coli in-
fection. Alternatively, our observation of a mostly short interval
between travel and infection supports the possibility of domestic
(within Australia and New Zealand) transmission of this resis-
tance. Transmission of ESC-R E. coli from others within the
household or communitywho have had recent travel to the Indian
subcontinentmay occur. Although the truemagnitude of risk and
the broader applicability require further study, this observation is
consistent with a previously published study from one of our par-
ticipating sites andwith other descriptions of household transmis-
sion (32, 33). Recently, “birth outside Europe” was identified as a
risk factor for infection by CTX-M-producing E. coli in another
study, although comparison with our data is complicated, as the
European study did not fully account for recent travel (31).
Our molecular epidemiology data serve to confirm a number
of key observations made in other regions. The first is a distinct
difference between the epidemiology of CTX-MESBLs and that of
other expanded-spectrum cephalosporinase enzymes, which may
be mediated by the differing modes of acquisition, phenotypes,
and characteristics of the E. coli strains harboring them (16, 34).
Second, the high proportion of the ST131 clone among ESBLs is
no surprise given its global prevalence (35). More surprising is its
predominance without significant fluoroquinolone use (6% of
all participants in this study), one of the likely drivers in other
regions (36). Exposure to this class of antimicrobials within Aus-
tralia and New Zealand is very low (5).
Male sex has been defined by other researchers as a risk factor
for community-onset ESC-R E. coli infection (23, 37–40) and be-
came significant in some of our alternative models. The patient
population of studies with this finding gives a clue to the etiology
of this risk. On the whole, they are of older age with frequent
health care exposure. This contrasts with studies conducted with a
more traditional UTI population of young females that did not
identify male sex as a risk factor (28, 29). In addition to males
experiencing an age-dependent rise in the overall rates of E. coli
infection (41), a limitation associated with case-control studies
may also contribute to this finding. Aging patients certainly expe-
rience changes in the nuances and dynamics of health care expo-
sure and other potential risk factors for ESC-R E. coli infection not
identified with the data corresponding to dichotomous measures
such as hospitalization and antimicrobial use that are most often
collected.
The strengths of our study include its prospective collaborative
nature, a geographically broad sample range, and the case-control
methodology used. The low background rates of ESC-R E. coli
infection in Australia and New Zealand have likely led to more
discrete exposures and easier delineation of temporal risks than in
communities where participants are frequently exposed to this
form of resistance.
Limitations of our study include themoderate sample size, rate
of nonrecruitment, and risk of bias due to an absence of blind
investigator or patient procedures and reliance on patient recall
for many exposures. Recruiting a higher ratio of controls (1:2 or
1:3) would have increased our study power andmight have delin-
eated further unidentified risks. The use of a third group of unin-
fected patients (a case-case-control design) would have allowed
for delineation of risk factors associated with de novo acquisition
of ESC-R E. coli, as opposed to delineation of risk factors for
ESC-R within those that have E. coli (42). However, pragmatic
limitations precluded these options.
Some unique features of Australia and New Zealand may limit
extrapolation of our findings to other regions. The exclusion of
day procedures in this study’s definition of health care exposure
correlated with our local epidemiology and would need to be re-
considered elsewhere. Furthermore, in cases in which blaCTX-M
was not the predominant ESC resistance mechanism in a local
population, risk data might differ.
The use of only hospital patients for recruitment allowed con-
sistent access to participants and samples, although it might limit
the applicability of some risks to the wider community. The ex-
clusion of patients unable to consent meant that we could not
define risks for patients in long-term-care facilities, a known res-
ervoir of ESBL E. coli in Australia and overseas (43–45).
In conclusion, we have defined a critical ESC-R risk period
after health care exposure among community-onset E. coli infec-
tions and demonstrated that ESC-R E. coli infection in a low-
prevalence settings may be driven by “export” from health care
exposure in the previous 6months and importation after travel to
regions with a high incidence of community ESBLs.
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